Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AIM AIM ImmunoTech	$2.70 +0.4%	$6.68	$2.33 ▼ $39.00	$2.06M	0.88	66,657 shs	71,231 shs
FAP abrdn Asia-Pacific Income Fund VCC	C$2.95 +1.0%	C$2.91	C$2.67 ▼ C$3.04	C$108.75M	0.54	56,461 shs	18,834 shs
OLY Olympia Financial Group	C$131.00 -0.5%	C$123.84	C$95.51 ▼ C$134.24	C$315.23M	0.27	1,944 shs	1,060 shs
WED Westaim	C$28.75 +0.5%	C$30.28	C$22.80 ▼ C$35.55	C$424.76M	0.39	14,676 shs	44,714 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AIM AIM ImmunoTech	+8.47%	+4.67%	-68.03%	-70.57%	-93.17%
FAP abrdn Asia-Pacific Income Fund VCC	0.00%	+0.34%	+1.38%	+0.34%	+6.14%
OLY Olympia Financial Group	+1.71%	+2.30%	+7.08%	+24.21%	+17.49%
WED Westaim	+0.42%	-3.21%	-5.27%	-9.49%	+624.05%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AIM AIM ImmunoTech	1.4496 of 5 stars	3.5	0.0	0.0	0.0	2.2	0.0	0.0
FAP abrdn Asia-Pacific Income Fund VCC	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OLY Olympia Financial Group	3.0102 of 5 stars	2.5	0.0	2.5	0.0	1.8	3.3	1.3
WED Westaim	0.0894 of 5 stars	0.0	0.0	2.5	0.0	2.1	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AIM AIM ImmunoTech	3.00	Buy	$275.00	10,085.19% Upside
FAP abrdn Asia-Pacific Income Fund VCC	0.00	N/A	N/A	N/A
OLY Olympia Financial Group	3.00	Buy	C$147.91	12.91% Upside
WED Westaim	0.00	N/A	C$7.75	-73.04% Downside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AIM AIM ImmunoTech	$121K	17.05	N/A	N/A	$0.20 per share	13.50
FAP abrdn Asia-Pacific Income Fund VCC	C$14.12M	7.70	C$0.45 per share	6.60	C$2.92 per share	1.01
OLY Olympia Financial Group	C$102.64M	3.07	C$11.24 per share	11.66	C$16.72 per share	7.83
WED Westaim	C$10.20M	41.65	C$28.66 per share	1.00	C$3.89 per share	7.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AIM AIM ImmunoTech	-$28.96M	-$24.68	N/A	N/A	N/A	-12,594.21%	-421.73%	-147.54%	N/A
FAP abrdn Asia-Pacific Income Fund VCC	C$11.23M	C$0.31	9.65	∞	N/A	79.52%	10.17%	2.92%	N/A
OLY Olympia Financial Group	C$24.45M	C$10.16	12.89	∞	N/A	23.82%	64.95%	35.88%	N/A
WED Westaim	C$4.52M	C$0.44	65.05	∞	N/A	44.28%	7.76%	7.60%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AIM AIM ImmunoTech	N/A	N/A	N/A	N/A	N/A
FAP abrdn Asia-Pacific Income Fund VCC	C$0.21	7.12%	N/A	68.71%	N/A
OLY Olympia Financial Group	C$7.20	5.50%	N/A	70.86%	N/A
WED Westaim	C$0.18	0.63%	N/A	40.72%	N/A

Latest FAP, WED, OLY, and AIM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/20/2025	OLY Olympia Financial Group	Monthly	C$0.60	5.76%	8/20/2025	8/29/2025	8/29/2025
7/22/2025	OLY Olympia Financial Group	Monthly	C$0.60	5.95%	7/22/2025	7/31/2025	7/31/2025
6/19/2025	OLY Olympia Financial Group	Monthly	C$0.60	6.28%	6/19/2025	6/30/2025	6/30/2025
6/10/2025	FAP abrdn Asia-Pacific Income Fund VCC	jun 25	C$0.02			6/23/2025	1/1/2000

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AIM AIM ImmunoTech	0.05	0.75	0.75
FAP abrdn Asia-Pacific Income Fund VCC	44.38	2.85	0.30
OLY Olympia Financial Group	6.00	3.32	1.59
WED Westaim	N/A	N/A	27.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AIM AIM ImmunoTech	12.02%
FAP abrdn Asia-Pacific Income Fund VCC	13.14%
OLY Olympia Financial Group	1.17%
WED Westaim	12.11%

Insider Ownership

Company	Insider Ownership
AIM AIM ImmunoTech	0.02%
FAP abrdn Asia-Pacific Income Fund VCC	0.31%
OLY Olympia Financial Group	34.63%
WED Westaim	9.25%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AIM AIM ImmunoTech	20	764,000	68.74 million	Not Optionable
FAP abrdn Asia-Pacific Income Fund VCC	N/A	36.86 million	N/A	Not Optionable
OLY Olympia Financial Group	325	2.41 million	N/A	Not Optionable
WED Westaim	3,240	14.77 million	N/A	Not Optionable

FAP, WED, OLY, and AIM Headlines

Recent News About These Companies

Westaim (CVE:WED) Shares Down 1% - Here's Why

August 1, 2025 | marketbeat.com

Westaim to Invest AUS$154 Million to Finance AUS$3.9 Billion Insignia Acquisition

July 24, 2025 | finance.yahoo.com

Westaim Commits AUS$154 Million for Insignia Acquisition

July 22, 2025 | tipranks.com

AM Best Assigns Credit Ratings to Ceres Life Insurance Company

July 9, 2025 | uk.finance.yahoo.com

Retail investors account for 49% of The Westaim Corporation's (CVE:WED) ownership, while private equity firms account for 36%

July 4, 2025 | finance.yahoo.com

Westaim Corporation Reports Q1 2025 Loss Amid Strategic Acquisition Costs

May 14, 2025 | tipranks.com

Westaim and CC Capital Finalize Transformative Insurance and Asset Management Deal

April 3, 2025 | tipranks.com

Westaim Full Year 2024 Earnings: US$0.75 loss per share (vs US$7.98 profit in FY 2023)

March 28, 2025 | finance.yahoo.com

Westaim nears completion of CC Capital deal

March 28, 2025 | insurancebusinessmag.comI

Westaim: Q4 Earnings Snapshot

March 27, 2025 | sfgate.com

Westaim Corporation Reports 2024 Financial Results Amid Strategic Restructuring

March 26, 2025 | tipranks.com

Westaim Completes Acquisition of ManhattanLife Insurance

February 5, 2025 | tipranks.com

Westaim Appoints Menes Chee as Independent Director Amid Strategic Transformation

January 7, 2025 | tipranks.com

The Westaim Corporation to Appoint Menes Chee as Independent Director

January 7, 2025 | financialpost.comF

Westaim Restructures and Relocates to Delaware

January 2, 2025 | tipranks.com

Westaim Shareholders Approve Major CC Capital Deal

December 19, 2024 | tipranks.com

The Westaim Corporation Shareholders Overwhelmingly Approve CC Capital Transaction

December 19, 2024 | financialpost.comF

The Westaim Corporation Reminds Shareholders to Cast their Vote for the Upcoming Special Meeting

December 12, 2024 | financialpost.comF

Westaim Names New CFO Amid Strategic Expansion

December 2, 2024 | tipranks.com

The Westaim Corporation Appoints Matthew Skurbe as Chief Financial Officer and Chief Risk Officer

December 2, 2024 | financialpost.comF

The Westaim Corporation Announces Amendment to Investment Agreement

November 19, 2024 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

FAP, WED, OLY, and AIM Company Descriptions

AIM ImmunoTech NYSE:AIM

$2.70 +0.01 (+0.37%)

Closing price 04:00 PM Eastern

Extended Trading

$2.61 -0.09 (-3.33%)

As of 04:51 PM Eastern

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

abrdn Asia-Pacific Income Fund VCC TSE:FAP

C$2.95 +0.03 (+1.03%)

As of 03:58 PM Eastern

The investment objective of the Company is to obtain current income and achieve incidental capital appreciation from investment in long-term securities. The Company seeks to obtain these objectives primarily from investment in long-term debt securities. The Company may invest up to 100 percent of its total assets in Asia-Pacific debt securities.

Olympia Financial Group TSE:OLY

C$131.00 -0.71 (-0.54%)

As of 03:56 PM Eastern

Olympia Financial Group Inc is engaged in providing financial services. The company's operating segments are Private Health Services Plan division which markets, sells and administers health and dental benefits to business owners; Investment Account Services division specializes in registered account administration; The Currency and Global Payments division provides corporations and private clients a personalized service for buying and selling foreign currencies; The Exempt Edge division is focused on Onboarding fees; The Corporate and Shareholder Services division, which acts as a cost centre and the Corporate Division.

Westaim CVE:WED

C$28.75 +0.15 (+0.52%)

As of 03:55 PM Eastern

The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time